Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
golimumab + apalutamide
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (golimumab), Oral (apalutamide)
01
Overview
**golimumab + apalutamide** is an investigational combination therapy for castration-resistant prostate cancer. Golimumab is a human monoclonal antibody that inhibits tumor necrosis factor alpha (TNF-α), a cytokine involved in systemic inflammation. Apalutamide is a next-generation androgen receptor inhibitor that blocks the androgen receptor at the ligand-binding domain, preventing androgen-induced transcriptional activity and subsequent tumor cell proliferation. The rationale for the combination is to simultaneously target hormone-driven proliferation and the inflammatory microenvironment in advanced prostate cancer[1][9].
- Other names
- golimumabapalutamide
02
Targets
AR (Adrenergic receptors)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on golimumab + apalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on golimumab + apalutamide.